The combination of AZD4635 and an anti-PD-L1 agent is thought to potentially shift the TME balance from an anti- to a more pro-inflammatory state, to then enable more complete tumor regressions—although treatment resistance has been observed in some animals. This evidence concerns the gene CD274 and neoplasm.